Emerging macrolide resistance in Bordetella pertussis in mainland China: Findings and warning from the global pertussis initiative
- PMID: 34327426
- PMCID: PMC8315362
- DOI: 10.1016/j.lanwpc.2021.100098
Emerging macrolide resistance in Bordetella pertussis in mainland China: Findings and warning from the global pertussis initiative
Abstract
Whooping cough, or pertussis, is a highly communicable infectious disease caused by the bacterium Bordetella pertussis. Vaccination once reduced the incidence of the disease, but a global resurgence of the infection happened during the past two decades, likely due to the waning immunity of vaccination. Macrolides such as erythromycin and azithromycin are the drugs of primary choice for treatment. In this personal view, we call for attention to macrolide-resistant B. pertussis (MRBP), which has emerged and prevailed in mainland China for years and are exclusively mediated by mutations in the 23S rRNA gene. Whether the prevalence of MRBP in China results from overuse of azithromycin in clinical medicine remains unknown. The incidence of MRBP is low in other countries, but this could be a technical illusion since China employs culture as the mainstream diagnostic method whereas nucleic-acid amplification test being widely used in other countries fail to test antimicrobial susceptibility. Given the increasingly frequent global travel that facilitates microbial transmission worldwide, there is a pressing need to perform international surveillance on MRBP to prevent the potential circulation of the organism. Finding alternative agents that possess good activity against B. pertussis is also urgently required.
Keywords: Macrolide; Pertussis; Resistance.
© 2021 The Authors.
Conflict of interest statement
Dr Feng declares no competing interests. During the conduct of the study, Dr. Chiu has received honoraria from Sanofi Pasteur, MSD, and Pfizer; Dr. Heininger and Dr. Hozbor have received honoraria from Sanofi Pasteur; Dr. von König has received honoraria from Sanofi Pasteur, GSK Biologicals SA, MSD, and Norvatis Vaccines. Dr. Tan has received grant from Sanofi Pasteur. Outside the submitted work, Dr. Tan has received grants from Merck, Pfizer, and Glaxo-Smith Kline.
Figures

Similar articles
-
Genotyping and macrolide-resistant mutation of Bordetella pertussis in East and South-East Asia.J Glob Antimicrob Resist. 2022 Dec;31:263-269. doi: 10.1016/j.jgar.2022.10.007. Epub 2022 Oct 18. J Glob Antimicrob Resist. 2022. PMID: 36270447 Free PMC article.
-
Molecular Evolution and Increasing Macrolide Resistance of Bordetella pertussis, Shanghai, China, 2016-2022.Emerg Infect Dis. 2023 Jan;30(1):29-38. doi: 10.3201/eid3001.221588. Emerg Infect Dis. 2023. PMID: 38146984 Free PMC article.
-
Emergence and spread of MT28 ptxP3 allele macrolide-resistant Bordetella pertussis from 2021 to 2022 in China.Int J Infect Dis. 2023 Mar;128:205-211. doi: 10.1016/j.ijid.2023.01.005. Epub 2023 Jan 9. Int J Infect Dis. 2023. PMID: 36632892
-
Macrolide Resistance in Bordetella pertussis: Current Situation and Future Challenges.Antibiotics (Basel). 2022 Nov 7;11(11):1570. doi: 10.3390/antibiotics11111570. Antibiotics (Basel). 2022. PMID: 36358225 Free PMC article. Review.
-
Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences.Int J Antimicrob Agents. 2021 Mar;57(3):106257. doi: 10.1016/j.ijantimicag.2020.106257. Epub 2020 Dec 11. Int J Antimicrob Agents. 2021. PMID: 33310117 Review.
Cited by
-
Epidemiological and clinical characteristics of pertussis in children and their close contacts in households: A cross-sectional survey in Zhejiang Province, China.Front Pediatr. 2022 Aug 18;10:976796. doi: 10.3389/fped.2022.976796. eCollection 2022. Front Pediatr. 2022. PMID: 36061393 Free PMC article.
-
Complete Genome Sequence of a Macrolide-Resistant Bordetella pertussis Isolated in Japan.Microbiol Resour Announc. 2022 Oct 20;11(10):e0071822. doi: 10.1128/mra.00718-22. Epub 2022 Sep 21. Microbiol Resour Announc. 2022. PMID: 36129277 Free PMC article.
-
Whole-genome comparison of two same-genotype macrolide-resistant Bordetella pertussis isolates collected in Japan.PLoS One. 2024 Feb 15;19(2):e0298147. doi: 10.1371/journal.pone.0298147. eCollection 2024. PLoS One. 2024. PMID: 38359004 Free PMC article.
-
Resurgence of Pertussis in the Gyeongnam Region of South Korea in 2023 and 2024.Vaccines (Basel). 2024 Nov 8;12(11):1261. doi: 10.3390/vaccines12111261. Vaccines (Basel). 2024. PMID: 39591164 Free PMC article.
-
A comprehensive resource for Bordetella genomic epidemiology and biodiversity studies.Nat Commun. 2022 Jul 1;13(1):3807. doi: 10.1038/s41467-022-31517-8. Nat Commun. 2022. PMID: 35778384 Free PMC article.
References
-
- Tan T., Dalby T., Forsyth K. Pertussis across the globe: recent epidemiologic trends from 2000 to 2013. Pediatr Infect Dis J. 2015;34(9):e222–e232. - PubMed
-
- Schellekens J., von Konig C.H., Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J. 2005;24(5 Suppl):S19–S24. - PubMed
-
- Guiso N., Liese J., Plotkin S. The global pertussis initiative: meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010. Hum Vaccin. 2011;7(4):481–488. - PubMed
-
- Centers for Disease C., Prevention Erythromycin-resistant Bordetella pertussis–Yuma County, Arizona, May-October 1994. Morb Mortal Wkly Rep. 1994;43(44):807–810. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous